TABLE 3.
Pharmacokinetic parameters of finafloxacin following multiple intravenous dosesa
| Treatment group(s) | Day | Dose (mg) | AUC0–tau (mg · h/liter) | Cmax (mg/liter) | t1/2 (h) | CL (ml/min) | Vz (liter) | RAobs |
|---|---|---|---|---|---|---|---|---|
| Groups 3 and 4 | 1 | 600 (n = 16) | 21.80 (28.0) | 8.84 (20.9) | ||||
| 7 | 24.3 (26.1) | 9.15 (18.9) | 11.9 (33.3) | 410 (26.9) | 423 (54.3) | 1.11 (6.59) | ||
| Group 5 | 1 | 800 (n = 8) | 32.0 (22.9) | 11.5 (15.5) | ||||
| 7 | 35.4 (29.7) | 37.8 (30.6) | 15.0 (18.4) | 376 (29.7) | 490 (35.6) | 1.11 (11.4) | ||
| Group 6 | 1 | 1,000 (n = 8) | 49.8 (33.4) | 17.1 (23.6) | ||||
| 7 | 64.1 (38.5) | 18.1 (31.2) | 16.9 (68.0) | 260 (38.5) | 381 (74.8) | 1.29 (16.1) |
a
Data are presented as geometric means (coefficients of variation [in percent]) for the area under the concentration-time curve during one dosing interval (AUC0–tau), the maximum concentration (Cmax) attained, the terminal elimination half-life (t1/2), elimination clearance (CL), volume of distribution at pseudoequilibrium (Vz), and observed accumulation ratios (RAobs) for n subjects receiving multiple 1 h intravenous infusions of finafloxacin (part B).